Global Single Cancer Screening Market Growth (Status and Outlook) 2024-2030

Global Single Cancer Screening Market Growth (Status and Outlook) 2024-2030

Product Code:1238064

Published Date: Nov 12,2024

Pages: 116

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

The global Single Cancer Screening market size is projected to grow from US$ 1355 million in 2024 to US$ 2975 million in 2030; it is expected to grow at a CAGR of 14.0% from 2024 to 2030.

Single cancer screening refers to screening procedures focused on a specific type of cancer, aimed at early detection to improve treatment outcomes and survival rates. This type of screening typically includes specific tests for certain cancers, such as mammography for breast cancer, Pap smears for cervical cancer, or blood tests for prostate cancer. The implementation of single cancer screening helps identify high-risk populations and provides timely interventions, effectively reducing cancer-related mortality.

United States market for Single Cancer Screening is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Single Cancer Screening is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Single Cancer Screening is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Single Cancer Screening players cover Grail, Exact Sciences, Oncognostic, Epigenomics, Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

LPI (LP Information)' newest research report, the “Single Cancer Screening Industry Forecast” looks at past sales and reviews total world Single Cancer Screening sales in 2023, providing a comprehensive analysis by region and market sector of projected Single Cancer Screening sales for 2024 through 2030. With Single Cancer Screening sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Single Cancer Screening industry.

This Insight Report provides a comprehensive analysis of the global Single Cancer Screening landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Single Cancer Screening portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Single Cancer Screening market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single Cancer Screening and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single Cancer Screening.

This report presents a comprehensive overview, market shares, and growth opportunities of Single Cancer Screening market by product type, application, key players and key regions and countries.

Segmentation by Type:
    Colorectal Cancer
    Liver Cancer
    Lung Cancer
    Other

Segmentation by Application:
    Hospital
    Physical Examination Center
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

Segmentation by Type:
    Colorectal Cancer
    Liver Cancer
    Lung Cancer
    Other

Segmentation by Application:
    Hospital
    Physical Examination Center
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Grail
    Exact Sciences
    Oncognostic
    Epigenomics
    Abbott
    Qiagen
    iStat Biomedical
    Genetron Health
    New Horizon Health
    Burning Rock
    Berry Oncology
    Shanghai Kunyuan Biotechnology